Continuous Femoral and Tibial Nerve Blocks in TKA Patients
NCT ID: NCT01680692
Last Updated: 2018-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
EARLY_PHASE1
2 participants
INTERVENTIONAL
2012-08-31
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA
NCT02730728
Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy
NCT02125903
Analgesic Effect of Peripheral Cutaneous Nerve Block of Knee Joint After Total Knee Arthroplasty
NCT05202730
Continuous Femoral Nerve Blockade and Readiness to Discharge Following Total Knee Arthroplasty
NCT00803348
Does Continuous Adductor Canal Nerve Block Improve the Quality of Recovery for Outpatient Total Knee Arthroplasty Patients?
NCT03038425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently at Texas Tech Health Science Center-El Paso and University Medical Center, about 95% of patient's undergoing total knee arthroplasty's (TKAs) receives a continuous femoral infusion and a single shot sciatic with an initial bolus of 30mL (femoral) and 20mL (sciatic) of Ropivicaine 0.5% and an infusion of Ropivicaine 0.2% at a rate of 10cc/hr (usually started post-op) for at least the first 48-72 hours post-operatively. For our study, Orthopedic clinic will provide a copy of the consent form to the subject so that they can review it, and if interested in participating in the study, the patient can then contact the Principal Investigator or Study Coordinator directly. After informed consent is obtained, patients will be randomized during that time using a numbering system enclosed in sealed envelopes. Group 1 will receive a pre-operative continuous femoral catheter and a post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine and 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr. Group 2 will receive a pre-operative continuous femoral catheter and a post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) and 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at the same rate and dosage as group 1. All nerve blocks performed will be placed using a nerve stimulator (with no twitches lower than 0.2mA) under ultrasound-guidance. Proper catheter placement will be confirmed by injecting 3mL of air and visualizing by ultrasound. Once confirmed, the bolus dose as mentioned earlier of either Ropivicaine 0.5% (femoral) or 0.2% (sciatic/tibial) will be injected. All TKA cases will be performed under general anesthesia with laryngeal mask airway. Considering the fact that by placing a selective continuous tibial catheter pre-operatively, we run the risk of the catheter being the surgical field during the case. For this reason, it was decided that placement after the procedure would be best. Therefore, the patient will be taken back to the block room post-operatively and a continuous tibial nerve catheter or single shot (depending on what group assigned) will be placed and bolused using the same technique as previously described. To detect a 30% reduction in the pain score from 3-4 to a 1-2 would be required for an observed post-operative pain control difference. In order to achieve a statistically significant result to detect the previously observed difference, a sample of 38 patients in each group (total of 76) would be required. Assuming a high consent rate and given the fact many TKA's it is projected that this study can be completed in approximately 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Continuous femoral and single shot sciatic nerve block
Will receive pre-operative continuous femoral catheter \& post-operative single shot sciatic with both given an initial bolus of 30 mL (femoral) 0.5% Ropivicaine \& 20mL (sciatic) 0.2% Ropivicaine. Following surgery the femoral infusion will be started, which will be running Ropivicaine 0.2 at 10cc/hr.
Ropivicaine
Infusion of local anesthetic for post-operative analgesia.
Continuous Femoral Nerve Catheter
Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
Continuous femoral and tibial peripheral nerve catheters
Patients will receive pre-operative continuous femoral catheter \& post-operative continuous tibial catheter with an initial bolus of 30 mL 0.5% Ropivicaine (femoral) \& 20mL 0.2% Ropivicaine (tibial), which will be followed by infusions post-operatively running at 10cc/hr.
Ropivicaine
Infusion of local anesthetic for post-operative analgesia.
Continuous Femoral Nerve Catheter
Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
Continuous Tibial Nerve Catheter
Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropivicaine
Infusion of local anesthetic for post-operative analgesia.
Continuous Femoral Nerve Catheter
Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
Continuous Tibial Nerve Catheter
Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiology Classification (ASA) 1, 2, or 3
Exclusion Criteria
* Under 18
* Pregnancy
* Presence of neurological disease or existing parasthesia
* Diabetes
* Chronic drug use
* Infection of leg
* American Society of Anesthesiology Classification (ASA) 4-6 (unstable conditions)
* History of allergy to local anesthetics or opioids
18 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Texas Tech University Health Sciences Center
OTHER
Texas Tech University Health Sciences Center, El Paso
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hana Teissler, MD
Role: PRINCIPAL_INVESTIGATOR
Texas Tech University Health Sciences Center- Paul L. Foster School of Medicine of El Paso
John Zaki, MD
Role: PRINCIPAL_INVESTIGATOR
Texas Tech University Health Sciences Center- Paul L. Foster School of Medicine of El Paso
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center of El Paso, Texas Tech University Health Sciences Center
El Paso, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E12094
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.